Login
Evidence Feed
About
Diagnostics
New
Top genes
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
SG301 IV
i
Other names:
SG301 IV
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
News
Trials
Company:
Sumgen Biotech
Drug class:
CD38 inhibitor
Related drugs:
‹
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
daratumumab (26)
isatuximab-irfc (11)
daratumumab and hyaluronidase-fihj (4)
SAR442257 (4)
BHV-1100 (1)
ISB 1342 (1)
K-NK004 (1)
MT-0169 (1)
SAR442085 (1)
MOR202 (1)
TAK-079 (1)
211At-OKT10-B10 (0)
FT538 (0)
FT555 (0)
FT576 (0)
GEN3014 (0)
IGM-2644 (0)
ISB 1442 (0)
ISB 2001 (0)
NY-338 (0)
SG2501 (0)
STI-1492 (0)
VP301 (0)
XmAb968 (0)
Y150 (0)
SAR650984 SC (0)
TAK-573 (0)
›
Associations
News
Trials
Filter by
Latest
5ms
A Clinical Study Comparing SG301 Plus Pomalidomide and Dexamethasone to Placebo Plus Pomalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma Patients (clinicaltrials.gov)
P3, N=360, Recruiting, Hangzhou Sumgen Biotech Co., Ltd.
5 months ago
New P3 trial • Combination therapy
|
dexamethasone • pomalidomide • SG301 IV
9ms
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
P1, N=61, Active, not recruiting, Hangzhou Sumgen Biotech Co., Ltd. | Withdrawn --> Active, not recruiting | Trial completion date: Oct 2022 --> Dec 2024 | Trial primary completion date: Sep 2022 --> Jun 2024
9 months ago
Enrollment closed • Trial completion date • Trial primary completion date
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV
almost2years
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
P1, N=0, Withdrawn, Hangzhou Sumgen Biotech Co., Ltd. | N=108 --> 0 | Not yet recruiting --> Withdrawn
almost 2 years ago
Enrollment change • Trial withdrawal
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV
almost4years
SG301 Safety Study in Subjects With Relapsed or Refractory Multiple Myeloma and Other Hematological Malignancies (clinicaltrials.gov)
P1, N=108, Not yet recruiting, Hangzhou Sumgen Biotech Co., Ltd.
almost 4 years ago
Clinical • New P1 trial
|
CD38 (CD38 Molecule)
|
CD38 expression
|
SG301 IV
Share via
^
^
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login
Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.
Sign up for FREE
Already have an account?
Login